FDA OKs Hitachi's PET/CT system
Hitachi Medical Systems America (HMSA) has received FDA 510(k) clearance to market its new Sceptre P3 PET/CT system in the United States.
The system combines three technologies in one: Lutetium oxyorthosilicate (LSO) PET technology, HMSA's fast quad-slice CT and connectivity to AVIA PACS. The system features dual attenuation correction (DAC Technology) and FDA approved Non-Rigid Fusion7D algorithm that provides precise registration by correcting for respiration differences between PET and CT acquisitions.
The Sceptre P3 is designed with a field upgrade capability and allows Sceptre dedicated PET customers an opportunity to cost effectively upgrade to the benefits of PET/CT. The "Evolve" upgrade program is available to all Sceptre dedicated PET scanners including both installed and forward production systems
HMSA previewed the Sceptre P3 at the 2004 Society of Nuclear Medicine (SNM) meeting held in mid-June in Philadelphia.
The system combines three technologies in one: Lutetium oxyorthosilicate (LSO) PET technology, HMSA's fast quad-slice CT and connectivity to AVIA PACS. The system features dual attenuation correction (DAC Technology) and FDA approved Non-Rigid Fusion7D algorithm that provides precise registration by correcting for respiration differences between PET and CT acquisitions.
The Sceptre P3 is designed with a field upgrade capability and allows Sceptre dedicated PET customers an opportunity to cost effectively upgrade to the benefits of PET/CT. The "Evolve" upgrade program is available to all Sceptre dedicated PET scanners including both installed and forward production systems
HMSA previewed the Sceptre P3 at the 2004 Society of Nuclear Medicine (SNM) meeting held in mid-June in Philadelphia.